Overview
BPC-157 is a synthetic peptide of fifteen amino acids, studied experimentally for tissue repair and injury responses; its evaluated forms include the free base and acetate salt.[1][2] Research on BPC-157 spans experimental muscle and tendon injuries, gastrointestinal injury models, and small human reports involving knee pain, bladder symptoms and intravenous administration.[3][4][5][6][7] These sources differ substantially in design, population, route, and the outcomes they measured, so they should not be treated as one body of interchangeable clinical evidence.[1][3][4][5][6][8][9][10][11][12] The guide separates reported symptom changes from evidence of tissue repair and distinguishes experimental findings from validated human treatment regimens.[1][3][4][5][6][8][9][10][11][12] Safety uncertainties, product identity, and the limits of combination research remain part of that assessment rather than being inferred from a proposed recovery mechanism.
Benefits
Does BPC-157 speed tendon or ligament healing?
The knee-pain case series measured subjective symptoms, without objective confirmation of tendon or ligament repair.[5] In a 2026 rat Achilles-repair experiment, BPC-157 alone did not significantly improve maximum load to failure versus control.[8] That experiment used four tendons per group for each endpoint, so its nonsignificant result does not establish that no effect exists.[8] Pain relief and tissue repair are different outcomes: a report of less pain does not show that a torn tendon has regained its structure or mechanical strength.[5] The rat experiment assessed surgically repaired Achilles tendons, so it also cannot determine whether BPC-157 accelerates recovery from the range of tendon injuries seen in clinical practice.[8]
What does the human knee-pain study show?
Of seventeen patients identified, sixteen were contacted; eleven of twelve receiving BPC-157 alone reported improvement.[5] The uncontrolled, retrospective design and subjective outcomes cannot separate a drug effect from recovery, expectation or other care.[5] The patients had different types of knee pain, and the study did not include a comparable group receiving placebo or usual care alone.[5] The finding is therefore a preliminary signal of reported symptom improvement, rather than evidence that BPC-157 treats a defined knee disorder or repairs damaged cartilage.[5]
What evidence supports muscle-injury recovery?
Rat experiments reported improved muscle-to-bone reattachment and recovery after muscle–tendon junction separation.[3][9] A separate rat muscle-crush experiment reported improved healing during corticosteroid exposure.[10] These induced injuries support further research but do not establish human recovery times, effective doses or safe drug combinations.[3][9][10] The experiments address different injuries and treatment conditions, making their results specific to those models rather than a single, established effect on muscle recovery.[3][9][10] They do not answer whether an athlete or a patient undergoing rehabilitation would regain strength sooner, return to activity earlier, or experience fewer complications.[3][9][10]
Does BPC-157 heal the gut or treat inflammatory bowel disease?
Studies in animals report reduced injury in rat models of gastric ulcers and concentrated-alcohol exposure.[4][11] FDA separately reviewed a small placebo-controlled ulcerative-colitis study reported only as a meeting abstract, with insufficient detail for a reliable effectiveness assessment.[1] Those findings do not establish a benefit for commercial oral BPC-157 products or nonspecific “leaky gut” symptoms.[1][4] Damage caused experimentally by concentrated alcohol is a different research problem from treating chronic inflammatory bowel disease in people.[11] The animal results provide a reason to investigate gastrointestinal effects, but the incomplete human report does not establish which patients would benefit, how large the benefit would be, or whether it would persist.[1][4][11]
Has BPC-157 been studied for bladder pain?
An uncontrolled retrospective report described twelve women treated by cystoscopic bladder injection; ten reported complete symptom resolution and two partial improvement.[6] The paper describes follow-up timing inconsistently, and the lack of a comparator prevents attributing improvement to BPC-157.[6] This procedure-specific report does not establish that oral or subcutaneous products treat bladder pain.[6] The small sample and retrospective symptom assessments make this an exploratory observation, not a controlled estimate of treatment benefit.[6] Its findings apply to the particular patients and bladder procedure described, and cannot supply a general treatment protocol for urinary symptoms.[6]
Safety
FDA identifies immunogenicity concerns and limited route-specific safety information.[13] The two-person intravenous pilot reported no adverse effects during three days of monitoring, but both participants had previous exposure.[7] This small, selected sample cannot establish routine or long-term safety.[7] The clinical-note preprint also describes neuropsychiatric, skin or injection-site, and gastrointestinal symptoms, without establishing causation or reliable event rates.[12] Three days of observation in two previously exposed adults provides little information about uncommon reactions, the consequences of repeated treatment, or effects that emerge after prolonged exposure.[7] The larger clinical-note report adds descriptions of symptoms encountered in practice, but its retrospective records cannot reliably distinguish adverse drug reactions from symptoms associated with illness or other treatments.[12]
Contraindications
FDA's 2026 assessment identified no carcinogenicity studies and incomplete reproductive testing for the evaluated BPC-157 substances and routes.[1] Those gaps leave pregnancy and cancer-related safety unresolved; they do not establish either a proven-safe population or a demonstrated human cancer effect.[1] These are missing safety assessments, rather than evidence that every potential risk has been excluded.[1] The available assessment therefore cannot define an evidence-based list of circumstances in which BPC-157 can be assumed safe, particularly where reproductive or cancer-related risks are the concern.[1]
Interactions
The human reports were not designed to establish drug-interaction safety.[5][7] Rat experiments involving corticosteroids do not establish compatibility in people.[10] Observations involving more than one treatment do not establish that a combination is safe or that the treatments act independently.[5][7] The reviewed human evidence consequently does not support a validated interaction list or a general assurance that adding BPC-157 to an existing regimen is safe.[5][7]
Forms & dosing
FDA's 2026 review found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal BPC-157.[1] This limits the ability to translate a dose used in one setting into an equivalent dose for another route.[1] A clinical dosing recommendation would require evidence connecting a defined formulation and exposure to a meaningful benefit and an acceptable safety profile, which this assessment does not establish for those routes.[1] Oral administration produced effects in some rat injury experiments, but those experiments did not measure clinical equivalence in humans.[3][4] A pharmacokinetic study examined intravenous and intramuscular administration in rats and dogs; it did not evaluate human oral absorption.[2] These sources do not establish that capsules and injections are interchangeable.[2][3] A response in an animal injury model and a measurement of drug exposure answer different questions; neither establishes that a marketed capsule delivers the same exposure or effects as an injection in a person.[2][3][4] Consequently, route-specific findings should remain attached to the formulation, species and administration method actually studied.[2][3][4]
Results & stopping
The knee-pain report used variable retrospective follow-up, so it cannot establish a reliable healing timeline or cycling schedule.[5] The clinical-note preprint recorded discontinuation for several reasons but did not test a tapering or withdrawal protocol.[12] Retrospective reports of improvement cannot determine the expected time to benefit for a new patient or show whether symptom changes correspond to healed tissue.[5] Likewise, records of discontinuation do not establish whether tapering is necessary or whether a particular cycle reduces adverse effects.[12]
Product quality
FDA’s assessment identified inconsistent substance naming and incomplete impurity characterization.[1] For injectable products, it also identifies sterility, bacterial endotoxins and particulates as relevant quality attributes; a purity percentage alone does not cover those attributes.[1] Identity, impurity characterization and the quality requirements of the intended route are separate questions; a reported percentage of chemical purity addresses only part of that assessment.[1] Even an analytically characterized substance does not establish that the finished formulation is clinically effective or safe for a particular use.[1]
Status
FDA's 2026 briefing states that neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug.[1] At the October 3, 2026 source check, FDA’s risk page listed BPC-157 under nominations withdrawn by their nominators.[13] Regulatory status needs to be read for the exact substance, finished product, indication, and jurisdiction being discussed. A research publication, a supplier listing, and a regulatory decision answer different questions, so none should be used as a substitute for the others.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
| Human and preclinical researchHuman case series indirect for structural repair; exploratory rat repair experiment.[5][8] The knee-pain case series measured subjective symptoms, without objective confirmation of tendon or ligament repair.[5] In a 2026 rat Achilles-repair experiment, BPC-157 alone did not significantly improve maximum load to failure versus control.[8] That experiment used four tendons per group for each endpoint, so its nonsignificant result does not establish that no effect exists.[8] Main limitation: Symptoms and preclinical endpoints do not establish human structural repair.[5][8] | ||
| Human researchUncontrolled retrospective case series.[5] Of seventeen patients identified, sixteen were contacted; eleven of twelve receiving BPC-157 alone reported improvement.[5] The uncontrolled, retrospective design and subjective outcomes cannot separate a drug effect from recovery, expectation or other care.[5] The patients had different types of knee pain, and the study did not include a comparable group receiving placebo or usual care alone.[5] Main limitation: No placebo or objective repair endpoint.[5] | ||
| Animal or cell researchControlled rat surgical and crush-injury experiments.[3][9][10] Rat experiments reported improved muscle-to-bone reattachment and recovery after muscle–tendon junction separation.[3][9] A separate rat muscle-crush experiment reported improved healing during corticosteroid exposure.[10] These induced injuries support further research but do not establish human recovery times, effective doses or safe drug combinations.[3][9][10] Main limitation: No direct human muscle-recovery trial in these studies.[3][9][10] | ||
| Animal or cell researchRat injury experiments; regulatory assessment of an abstract-only human trial.[1][4][11] Studies in animals report reduced injury in rat models of gastric ulcers and concentrated-alcohol exposure.[4][11] FDA separately reviewed a small placebo-controlled ulcerative-colitis study reported only as a meeting abstract, with insufficient detail for a reliable effectiveness assessment.[1] Those findings do not establish a benefit for commercial oral BPC-157 products or nonspecific “leaky gut” symptoms.[1][4] Main limitation: Human evidence includes an incompletely reported meeting abstract, with insufficient detail to assess effectiveness reliably.[1][4][11] | ||
| Human researchUncontrolled retrospective case series.[6] An uncontrolled retrospective report described twelve women treated by cystoscopic bladder injection; ten reported complete symptom resolution and two partial improvement.[6] The paper describes follow-up timing inconsistently, and the lack of a comparator prevents attributing improvement to BPC-157.[6] This procedure-specific report does not establish that oral or subcutaneous products treat bladder pain.[6] Main limitation: No comparator; inconsistent timing; route-specific procedure.[6] | ||
| Human researchRetrospective clinical-note study; preprint not peer reviewed.[12] A September 2026 preprint identified 1,039 documented users; 279 of the 354 with a recorded response direction had reported improvement, while 685 lacked a recorded response direction.[12] It was not peer reviewed at this check, and missing outcomes, co-treatments and no control group prevent interpreting these counts as an effectiveness rate.[12] The much larger number of documented users improves the description of real-world use, but it does not resolve the missing outcomes or introduce the comparison group needed to estimate a treatment effect.[12] Main limitation: Selection, missingness and confounding.[12] | ||
| Human researchTwo-person safety pilot; uncontrolled EHR preprint.[7][12] The two-person intravenous pilot reported no adverse effects during three days of monitoring, but both participants had previous exposure.[7] This small, selected sample cannot establish routine or long-term safety.[7] The clinical-note preprint also describes neuropsychiatric, skin or injection-site, and gastrointestinal symptoms, without establishing causation or reliable event rates.[12] Main limitation: Brief monitoring and nonstandard adverse-event ascertainment.[7][12] | ||
| Animal or cell researchControlled in vitro receptor-expression experiment.[14] A cell-culture study found increased growth-hormone receptor expression in rat tendon fibroblasts.[14] That is different from demonstrating increased circulating growth hormone, and it does not validate combining BPC-157 with growth-hormone secretagogues in people.[14] Receptors describe how a cell may respond to a hormone; this experiment did not measure a rise in blood growth-hormone levels or test a clinical benefit from raising those levels.[14] Main limitation: Receptor expression is not systemic hormone concentration.[14] | ||
| Human and preclinical researchSmall nonrandom human subgroup and randomized exploratory rat study.[5][8] The knee case series included only four recipients of BPC-157 plus thymosin beta-4 and did not randomize treatment.[5] A rat Achilles study found no additional benefit from its BPC-157/TB-500 combination over monotherapy, with small endpoint samples.[8] Neither study establishes the benefit or safety of commercial peptide blends in people.[5][8] Main limitation: Formulation and route cannot be generalized.[5][8] | ||
| Animal or cell researchAnimal route-specific experiments; no human head-to-head comparison in these sources.[2][3][4] Oral administration produced effects in some rat injury experiments, but those experiments did not measure clinical equivalence in humans.[3][4] A pharmacokinetic study examined intravenous and intramuscular administration in rats and dogs; it did not evaluate human oral absorption.[2] These sources do not establish that capsules and injections are interchangeable.[2][3] Main limitation: Animal responses are not human bioavailability.[2][3][4] | ||
| Human and preclinical researchAnimal LC-MS/MS pharmacokinetics; human safety pilot without PK assays.[2][7] The pharmacokinetic paper reported mean intact-peptide half-lives below thirty minutes in tested rat and dog regimens.[2] The two-person human intravenous paper measured clinical laboratory markers rather than BPC-157 concentrations.[7] These studies therefore do not establish a human half-life or dosing frequency.[2][7] Main limitation: Intact peptide must be distinguished from total radiolabel.[2][7] |
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy
BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment
BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats
- Population
- Rat
- Finding and limits
- The investigators reported preservation of retinal layers after L-NAME-induced injury in rats. This experimental eye-injection model does not establish human visual or neurological benefit.
Relevant PDF pages: 6, 4.
Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157
Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats
Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
- Population
- Human
- Finding and limits
- Ten of twelve women reported complete symptom resolution after bladder injections, and two reported partial improvement. There was no control group, and questionnaire timing is described inconsistently.
Relevant PDF pages: 3, 2.
Effects of BPC-157 and TB-500 on Achilles tendon healing
- Population
- Male Sprague-Dawley rats
- Finding and limits
- BPC-157 alone did not significantly improve maximum load to failure versus control; the combination showed no additional benefit over monotherapy. Only four tendons per group contributed to each endpoint, so nonsignificance does not prove no effect.
Relevant PDF pages: 5, 14.
Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short- Bowel Rats
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME
Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157
- Population
- Rat
- Finding and limits
- Aortic tissue spectra differed between treated and control rats. This exploratory study used five animals per group; multiple tissue sections were technical samples, not additional animals.
Relevant PDF pages: 7.
Impact of pentadecapeptide BPC 157 on muscle healing
- Population
- Male Wistar albino rats
- Finding and limits
- BPC-157 improved measured healing after rat muscle crush during methylprednisolone exposure. This experiment cannot establish a safe corticosteroid combination in humans.
Relevant PDF pages: 3, 1.
In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
- Population
- Human
- Finding and limits
- Sixteen patients were contacted after knee injections; eleven of twelve receiving BPC-157 alone reported improvement. The study had no control group or objective confirmation of tissue repair.
Relevant PDF pages: 3.
Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot
Modulatory effects of BPC 157 on vasomotor tone and the activation of Src‑Caveolin‑1‑endothelial nitric oxide synthase pathway
Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy
Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157
- Population
- Rat
- Finding and limits
- The investigators reported collateral-vessel recruitment and reduced pressure disturbances after mesenteric vessel ligation. This acute surgical rat experiment cannot establish a clinical vascular treatment.
Relevant PDF pages: 8.
Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension
Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157
Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
- Population
- Rat-derived Achilles tendon fibroblasts
- Finding and limits
- BPC-157 increased growth-hormone receptor expression in cultured rat tendon fibroblasts. Receptor expression in a culture does not demonstrate higher circulating growth hormone in people.
Relevant PDF pages: 3.
Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion
Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats
- Population
- Rat
- Finding and limits
- The investigators reported smaller clots and less ascites after experimental vena-cava obstruction. These results do not establish human liver-disease treatment or anticoagulant compatibility.
Relevant PDF pages: 6.
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
- Population
- Rat and dog
- Finding and limits
- Reported mean half-lives of intact BPC-157 were below thirty minutes in the tested rat and dog regimens. These findings do not establish a human half-life or dosing interval.
Relevant PDF pages: 2, 13.
Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats
- Population
- Rat
- Finding and limits
- BPC-157 reduced ulcer area in chemically or surgically induced rat gastric-injury models. The paper contains inconsistent comparator dose units and does not establish benefit for human digestive conditions.
Relevant PDF pages: 2.
Robert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157
- Population
- Rat
- Finding and limits
- The investigators reported less gastric damage after concentrated alcohol injury in rats. The thirty-minute model does not establish protection from drinking alcohol in people.
Relevant PDF pages: 8.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
- Population
- Human
- Finding and limits
- Two previously exposed adults underwent three days of laboratory and symptom monitoring, with no adverse effects reported by the authors. This was not a pharmacokinetic study and cannot establish long-term safety.
Relevant PDF pages: 4, 2.
Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats
Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats
Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal
- Population
- Rat
- Finding and limits
- The investigators reported improvements after early and delayed treatment in monocrotaline-induced pulmonary hypertension. The findings do not establish a treatment for human pulmonary hypertension.
Relevant PDF pages: 5.
Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats
- Population
- Rat
- Finding and limits
- BPC-157 reduced pressure disturbances and organ injury in acute rat experiments. The acute animal model and conflicting exposure-duration descriptions limit interpretation.
Relevant PDF pages: 7, 6.
Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
- Population
- Male Wistar rats
- Finding and limits
- The investigators reported functional and muscle-size recovery after separating the muscle–tendon junction in rats. This surgical model does not establish recovery from human sports injuries.
Relevant PDF pages: 7, 11.
Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS
Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights
The anti-nociceptive effect of BPC-157 on the incisional pain model in rats
The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats
Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats
Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes
- Population
- Human
- Finding and limits
- This unreviewed preprint identified 1,039 documented users, with response direction missing for 685. Missing outcomes, co-treatments and an absent control group prevent a treatment-effect estimate.
Relevant PDF pages: 9, 11.
Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats
- Population
- Male albino Wistar rats
- Finding and limits
- The investigators reported improved quadriceps reattachment and walking after experimentally detaching muscle from bone. The oral rat regimen does not establish human oral absorption or recovery.
Relevant PDF pages: 8.
Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing
- Population
- Male Wistar albino rats and endothelial-cell culture
- Finding and limits
- Animal tissues showed changes in angiogenic-marker timing, while the cell-culture tube-branching assay found no significant difference. These are assay-specific findings, with inconsistent concentration units reported in the paper.
Relevant PDF pages: 2, 3.
BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1
- Population
- Human endothelial-cell cultures and rodent tissue-injury models
- Finding and limits
- The paper reports endothelial-cell tube formation and an FBXO22/BACH1 mechanism. Conflicting animal routes, doses and sample descriptions prevent a reliable animal dose–response interpretation here.
Animal dose and sample-size claims are withheld pending clarification of reporting discrepancies.
Relevant PDF pages: 3, 4.
FAQs
Does the large clinical-note study prove BPC-157 works?
A September 2026 preprint identified 1,039 documented users; 279 of the 354 with a recorded response direction had reported improvement, while 685 lacked a recorded response direction.[12] It was not peer reviewed at this check, and missing outcomes, co-treatments and no control group prevent interpreting these counts as an effectiveness rate.[12] The much larger number of documented users improves the description of real-world use, but it does not resolve the missing outcomes or introduce the comparison group needed to estimate a treatment effect.[12]
Does BPC-157 increase growth hormone?
A cell-culture study found increased growth-hormone receptor expression in rat tendon fibroblasts.[14] That is different from demonstrating increased circulating growth hormone, and it does not validate combining BPC-157 with growth-hormone secretagogues in people.[14] Receptors describe how a cell may respond to a hormone; this experiment did not measure a rise in blood growth-hormone levels or test a clinical benefit from raising those levels.[14]
Does combining BPC-157 with TB-500 work better?
The knee case series included only four recipients of BPC-157 plus thymosin beta-4 and did not randomize treatment.[5] A rat Achilles study found no additional benefit from its BPC-157/TB-500 combination over monotherapy, with small endpoint samples.[8] Neither study establishes the benefit or safety of commercial peptide blends in people.[5][8] To evaluate an interaction, the evidence needs to address the substances together and describe the outcome being monitored. Separate studies cannot establish the combined effect, and an unanswered interaction question should remain an uncertainty rather than becoming reassurance.
What is known about BPC-157’s half-life?
The pharmacokinetic paper reported mean intact-peptide half-lives below thirty minutes in tested rat and dog regimens.[2] The two-person human intravenous paper measured clinical laboratory markers rather than BPC-157 concentrations.[7] These studies therefore do not establish a human half-life or dosing frequency.[2][7] A short animal plasma half-life also does not, by itself, tell us how long a biological effect lasts or how frequently a person would need treatment.[2]
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for BPC-157.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
26 sources
- FDA Briefing Document: BPC-157-related bulk drug substances, July 2026 Pharmacy Compounding Advisory Committee (2026)Regulatory assessmentSave study
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs (2022)Primary research · PreclinicalReview status · PendingSave study
- Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats (2025)Primary research · PreclinicalReview status · PendingSave study
- Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats (2004)Primary research · PreclinicalReview status · PendingSave study
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (2021)Primary research · Human studyRead review · DraftSave study
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (2024)Primary research · Human studyRead review · DraftSave study
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (2025)Primary research · Human studyRead review · DraftSave study
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (2026)Primary research · PreclinicalRead review · DraftSave study
- Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats (2021)Primary research · PreclinicalReview status · PendingSave study
- Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application (2010)Primary research · PreclinicalReview status · PendingSave study
- Robert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157 (2021)Primary research · PreclinicalReview status · PendingSave study
- Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes (2026)Primary research · Preprint, not peer reviewedReview status · PendingSave study
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Accessed 2026-10-03)Regulatory assessmentSave study
- Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts (2014)Primary research · PreclinicalRead review · DraftSave study
- Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing (2009)Primary research · PreclinicalReview status · PendingSave study
- BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1 (2026)Primary research · PreclinicalReview status · PendingSave study
- BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats (2021)Primary research · PreclinicalReview status · PendingSave study
- Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal (2021)Primary research · PreclinicalReview status · PendingSave study
- Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157 (2021)Primary research · PreclinicalReview status · PendingSave study
- Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats (2020)Primary research · PreclinicalReview status · PendingSave study
- Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats (2021)Primary research · PreclinicalReview status · PendingSave study
- Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157 (2022)Primary research · PreclinicalReview status · PendingSave study
- Chronic Triceps Tendinopathy BPC-157 Inquiries
- BPC-157 For Fully Body Tendonosis
- Oral vs. injectable bpc157
- Injectable Wolverine Stack vs Oral/Tablet BPC-157 + TB-500 — Is There a Difference?
Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions
